Business

Sunovion to buy Elevation Pharmaceuticals in a deal with a $100m upfront payment

Sunovion Pharmaceuticals Inc., the Marlborough subsidiary of a Japanese drug company, has agreed to buy Elevation­ Pharmaceuticals Inc., a privately held company specializing in the development of aerosol therapies for patients with respiratory diseases.

Sunovion will make an upfront payment of $100 million to shareholders of California-based Elevation when the deal closes. The agreement also calls for milestone payments of up to $90 million if an Elevation Pharmaceuticals drug candidate achieves certain goals. If the drug candidate gets regulatory approval, Sunovion said it could make commercial milestone payments of up to $210 million. Subsequent payments up to $30 million could occur.

Advertisement

An Elevation drug candidate referenced in the sales agreement is EP-101, a potential treatment for chronic obstructive pulmonary disease.

Sunovion, formerly Sepracor, was bought by Dainippon Sumitomo Pharma in 2009.

Chris Reidy

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com